ONCAlert | 2018 ASCO Annual Meeting

KEYNOTE-010 Shows Overall Survival Benefit of Pembrolizumab in NSCLC

Roy S. Herbst, MD, PhD
Published Online: 7:48 PM, Wed December 7, 2016

Roy. S. Herbst, MD, PhD, professor of Medicine (Medical Oncology), professor of Pharmacology, chief of Medical Oncology, Yale Cancer Center, discusses the phase III KEYNOTE-010 study, in which pembrolizumab (Keytruda) provided superior overall survival over docetaxel in patients with previously treated, PD-L1-expressing advanced non-small cell lung cancer (NSCLC). He discussed these results during an interview at the IASLC 17th World Conference on Lung Cancer.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.